Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Emerg Infect Dis 2007 Mar 10;13(3):380-7
N. Sarita Shah *1, Abigail Wright,† Gill-Han Bai,‡2 Lucia Barrera,§2 Fadila Boulahbal,¶2 Nuria Martín-Casabona,#2 Francis Drobniewski,**2 Chris Gilpin,††2 Marta Havelková,‡‡2 Rosario Lepe,§§2 Richard Lumb,¶¶2Beverly Metchock,*2 Françoise Portaels,##2 Maria Filomena Rodrigues,***2 Sabine Rüsch-Gerdes,†††2 Armand Van Deun,##2 Veronique Vincent,‡‡‡2,3 Kayla Laserson,* Charles Wells,* and J. Peter Cegielski*
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †World Health Organization, Geneva, Switzerland; ‡Korean Institute of Tuberculosis, Seoul, Republic of Korea; §National Institute of Infectious Diseases, Buenos Aires, Argentina; ¶Institut Pasteur d'Algérie, Alger, Algeria; #Hospital Universitaris Vall d'Hebron, Barcelona, Spain; **Health Protection Agency, London, United Kingdom; ††Prince Charles Hospital, Brisbane, Queensland, Australia; ‡‡National Institute of Public Health, Scrobarova, Czech Republic; §§Institute of Public Health of Chile,
Providencia Santiago, Santiago, Chile; ¶¶Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia; ##Institute of Tropical Medicine, Antwerp, Belgium; ***National Institute of Health, Porto, Portugal; †††National Reference Center for Mycobacteria, Borstel, Germany; and ‡‡‡Institut Pasteur, Paris, France
Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000–2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.
2007-03-10
eid2007-03-380
Copyright © 2007 - Shah, et al., licensee CDC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
2007. AEGiS.
Download full-text PDF